HRP20210548T1 - Spojevi amino-triazolopiridina i njihova uporaba u liječenju raka - Google Patents
Spojevi amino-triazolopiridina i njihova uporaba u liječenju raka Download PDFInfo
- Publication number
- HRP20210548T1 HRP20210548T1 HRP20210548TT HRP20210548T HRP20210548T1 HR P20210548 T1 HRP20210548 T1 HR P20210548T1 HR P20210548T T HRP20210548T T HR P20210548TT HR P20210548 T HRP20210548 T HR P20210548T HR P20210548 T1 HRP20210548 T1 HR P20210548T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- compound
- formula
- amino
- triazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436619P | 2016-12-20 | 2016-12-20 | |
| PCT/EP2017/083625 WO2018114999A1 (en) | 2016-12-20 | 2017-12-19 | Amino-triazolopyridine compounds and their use in treating cancer |
| EP17825829.9A EP3558997B1 (en) | 2016-12-20 | 2017-12-19 | Amino-triazolopyridine compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210548T1 true HRP20210548T1 (hr) | 2021-05-14 |
Family
ID=60937727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210548TT HRP20210548T1 (hr) | 2016-12-20 | 2017-12-19 | Spojevi amino-triazolopiridina i njihova uporaba u liječenju raka |
Country Status (39)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3558997T3 (da) | 2016-12-20 | 2021-04-19 | Astrazeneca Ab | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer |
| TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| WO2020186211A1 (en) * | 2019-03-13 | 2020-09-17 | The Uab Research Foundation | Methods and compositions for treating polyoma virus infection |
| TWI899080B (zh) | 2019-05-27 | 2025-10-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｄｎａ依賴性蛋白激酶抑制劑 |
| US20210008161A1 (en) | 2019-06-17 | 2021-01-14 | Crispr Therapeutics Ag | Methods and compositions for improved homology directed repair |
| WO2021098813A1 (zh) * | 2019-11-22 | 2021-05-27 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的嘧啶并吡咯类螺环化合物及其衍生物 |
| WO2021104277A1 (zh) * | 2019-11-25 | 2021-06-03 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的嘧啶并咪唑类化合物 |
| PH12022551280A1 (en) * | 2019-11-26 | 2024-01-08 | Primmune Therapeutics Inc | Tlr7 agonists |
| KR102786205B1 (ko) | 2019-12-31 | 2025-03-31 | 청두 바이위 파머수티컬 씨오., 엘티디 | 퓨린 유도체 및 의학에서의 그의 용도 |
| CN113121538B (zh) * | 2019-12-31 | 2023-04-21 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| WO2021136461A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| CN113493471B (zh) * | 2020-04-03 | 2024-06-11 | 山东轩竹医药科技有限公司 | 杂芳环类激酶抑制剂 |
| BR112022020962A2 (pt) * | 2020-04-17 | 2022-12-06 | Chengdu Baiyu Pharmaceutical Co Ltd | Derivados de imidazolidinona e uso médico dos mesmos |
| WO2021213460A1 (zh) * | 2020-04-23 | 2021-10-28 | 山东轩竹医药科技有限公司 | 三并环类激酶抑制剂 |
| KR20230017783A (ko) | 2020-04-28 | 2023-02-06 | 인텔리아 테라퓨틱스, 인크. | 시험관내 세포 전달 방법 |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2022017368A1 (zh) * | 2020-07-20 | 2022-01-27 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
| CN114249753A (zh) * | 2020-09-22 | 2022-03-29 | 山东轩竹医药科技有限公司 | 三唑并吡啶类激酶抑制剂 |
| CA3192868A1 (en) * | 2020-09-24 | 2022-03-31 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
| CN114634522A (zh) * | 2020-12-15 | 2022-06-17 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
| EP4263829A1 (en) | 2020-12-17 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
| TW202241901A (zh) * | 2020-12-21 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮衍生物、其製備方法及其在醫藥上的應用 |
| CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
| TW202229281A (zh) * | 2020-12-24 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮類化合物、其製備方法及其在醫藥上的應用 |
| CN116917288B (zh) * | 2021-03-22 | 2026-04-14 | 成都赜灵生物医药科技股份有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| US20240300977A1 (en) * | 2021-04-17 | 2024-09-12 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
| TWI812223B (zh) * | 2021-05-19 | 2023-08-11 | 大陸商再鼎醫藥（上海）有限公司 | 雜環取代的嘌呤酮衍生物的鹽型及晶型 |
| CN117377676B (zh) * | 2021-06-29 | 2026-04-07 | 康百达（四川）生物医药科技有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
| CN116023394B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023393B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023395B (zh) * | 2021-10-25 | 2025-07-15 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| WO2023220418A2 (en) * | 2022-05-13 | 2023-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| CR20250267A (es) | 2022-12-06 | 2026-01-14 | Astrazeneca Ab | Inhibidores de polq |
| EP4720069A4 (en) * | 2023-07-21 | 2026-07-22 | Wei Zhong | Substituted 2-AMINO-9-(3,3-DIFLOOROPIPERIDIN-4-YL)-7,9-DIHYDRO-8H-PURIN-8-ONE COMPOUNDS AND THEIR USE IN CANCER TREATMENT |
| WO2025049481A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025181336A1 (en) | 2024-03-01 | 2025-09-04 | Cellectis Sa | Compositions and methods for hbb-editing in hspc |
| WO2025248119A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors |
| TW202608880A (zh) | 2024-05-31 | 2026-03-01 | 瑞典商阿斯特捷利康公司 | Ｐｏｌｑ抑制劑 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| EP1719761A4 (en) | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | NEW HETEROCYCLIC CONNECTION |
| JP5190271B2 (ja) * | 2005-01-14 | 2013-04-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤としての５員の環付加複素環式ピリミジン |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20090023723A1 (en) | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| JP2009511527A (ja) | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Ｓｙｋ阻害物質としてのピロロピリミジン誘導体 |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| ES2627352T3 (es) | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
| PL2168966T3 (pl) | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
| EP2212326A1 (en) | 2007-08-23 | 2010-08-04 | AstraZeneca AB | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| BR112012019459A2 (pt) | 2010-02-03 | 2017-10-17 | Signal Pharm Llc | identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. |
| US20130035336A1 (en) | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| TWI557121B (zh) | 2011-04-21 | 2016-11-11 | 原真股份有限公司 | 新穎激酶抑制劑 |
| UY34032A (es) | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| JP6121658B2 (ja) | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| CN103998036B (zh) | 2011-10-19 | 2017-05-31 | 西格诺药品有限公司 | 利用tor激酶抑制剂治疗癌症 |
| EP2825168B1 (en) * | 2012-03-15 | 2018-05-09 | Signal Pharmaceuticals, LLC | Treatment of cancer with tor kinase inhibitors |
| CN102675897B (zh) | 2012-05-18 | 2015-04-29 | 陕西师范大学 | 硫脲/脲芳胺染料及其制备方法和应用 |
| CN103864792B (zh) | 2012-12-12 | 2017-01-18 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮并环类化合物 |
| AU2014223501A1 (en) | 2013-02-28 | 2015-09-17 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| NO2714752T3 (enExample) | 2014-05-08 | 2018-04-21 | ||
| DK3558997T3 (da) | 2016-12-20 | 2021-04-19 | Astrazeneca Ab | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer |
-
2017
- 2017-12-19 DK DK17825829.9T patent/DK3558997T3/da active
- 2017-12-19 CA CA3046339A patent/CA3046339C/en active Active
- 2017-12-19 UA UAA201907754A patent/UA123032C2/uk unknown
- 2017-12-19 PE PE2019001276A patent/PE20191474A1/es unknown
- 2017-12-19 MY MYPI2019003492A patent/MY183036A/en unknown
- 2017-12-19 SM SM20210225T patent/SMT202100225T1/it unknown
- 2017-12-19 AU AU2017384388A patent/AU2017384388B2/en active Active
- 2017-12-19 MA MA47079A patent/MA47079B1/fr unknown
- 2017-12-19 SI SI201730707T patent/SI3558997T1/sl unknown
- 2017-12-19 PT PT178258299T patent/PT3558997T/pt unknown
- 2017-12-19 CN CN201780078065.XA patent/CN110177791B/zh active Active
- 2017-12-19 PL PL17825829T patent/PL3558997T3/pl unknown
- 2017-12-19 US US15/846,679 patent/US10407446B2/en active Active
- 2017-12-19 ES ES17825829T patent/ES2867274T3/es active Active
- 2017-12-19 WO PCT/EP2017/083625 patent/WO2018114999A1/en not_active Ceased
- 2017-12-19 JO JOP/2019/0151A patent/JOP20190151B1/ar active
- 2017-12-19 CR CR20190301A patent/CR20190301A/es unknown
- 2017-12-19 MX MX2019007189A patent/MX390535B/es unknown
- 2017-12-19 HU HUE17825829A patent/HUE054548T2/hu unknown
- 2017-12-19 EP EP17825829.9A patent/EP3558997B1/en active Active
- 2017-12-19 NZ NZ755222A patent/NZ755222A/en unknown
- 2017-12-19 RS RS20210447A patent/RS61701B1/sr unknown
- 2017-12-19 JP JP2019533052A patent/JP6883653B2/ja active Active
- 2017-12-19 LT LTEP17825829.9T patent/LT3558997T/lt unknown
- 2017-12-19 AR ARP170103582A patent/AR110400A1/es active IP Right Grant
- 2017-12-19 HR HRP20210548TT patent/HRP20210548T1/hr unknown
- 2017-12-19 EA EA201991399A patent/EA037745B1/ru unknown
- 2017-12-19 BR BR112019012217-6A patent/BR112019012217B1/pt active IP Right Grant
- 2017-12-19 PH PH1/2019/501350A patent/PH12019501350B1/en unknown
- 2017-12-19 KR KR1020197021026A patent/KR102220971B1/ko active Active
- 2017-12-20 TW TW106144799A patent/TWI776835B/zh active
-
2019
- 2019-06-06 IL IL267158A patent/IL267158B/en active IP Right Grant
- 2019-06-17 DO DO2019000168A patent/DOP2019000168A/es unknown
- 2019-06-19 CL CL2019001714A patent/CL2019001714A1/es unknown
- 2019-06-20 EC ECSENADI201944159A patent/ECSP19044159A/es unknown
- 2019-06-20 NI NI201900062A patent/NI201900062A/es unknown
- 2019-07-17 ZA ZA2019/04695A patent/ZA201904695B/en unknown
- 2019-07-19 CO CONC2019/0007810A patent/CO2019007810A2/es unknown
- 2019-07-30 US US16/526,219 patent/US11136340B2/en active Active
-
2021
- 2021-04-27 CY CY20211100360T patent/CY1124239T1/el unknown
- 2021-08-27 US US17/459,049 patent/US11746118B2/en active Active
-
2023
- 2023-07-10 US US18/349,220 patent/US20240124492A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504107A5 (enExample) | ||
| ES2927860T3 (es) | Compuestos heterocíclicos bicíclicos sustituidos como inhibidores de PRMT5 | |
| SI3140303T1 (en) | Compounds of imidazo (4,5-c) quinolin-2-one and their use in the treatment of cancer | |
| HRP20210149T1 (hr) | Derivati 8-[6-[3-(amino)propoksi]-3-piridil]-1-izopropil-imidazo[4,5-c]kinolin-2-ona kao selektivni modulatori ataxia telangiectasia mutacije (atm) kinaze za liječenje raka | |
| AU2005278292B2 (en) | Novel substituted imidazole derivatives | |
| UA126177C2 (uk) | Похідні 2-амінопіридину або 2-амінопіримідину як інгібітори циклінзалежної кінази | |
| FI3888658T3 (fi) | eIF4A:ta inhiboivia yhdisteitä ja niihin liittyviä menetelmiä | |
| NZ711948A (en) | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one | |
| MX2021001096A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
| EP3172214A1 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof | |
| JP2018531226A5 (enExample) | ||
| RU2018120492A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| ES2602965T3 (es) | Inhibidores de aril lactama quinasa | |
| WO2016015604A1 (en) | Compounds as cdk small-molecule inhibitors and uses thereof | |
| ME02635B (me) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| AU2012339499A1 (en) | Aminoquinazoline derivatives and their salts and methods of use | |
| RS61281B1 (sr) | Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora | |
| CN102241678B (zh) | 含有脂环结构化合物的抗肿瘤作用与应用 | |
| JP2018504449A5 (enExample) | ||
| AU2020319058A1 (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| EA201791274A1 (ru) | ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV) | |
| BR112015023705A8 (pt) | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) | |
| SI2796458T1 (en) | CRYSTALINIC SODIUM RALTEGRAVIR SOLUTIONS | |
| AU2022202886A1 (en) | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | |
| RU2016116777A (ru) | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания |